newsfilter
← Latest News
ACCESS Newswire·

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

- STAR-1 topline results expected in first quarter of 2025 -- About 30 million acne patients seek treatment in the U.S. each year -- DMT310, if approved, could be the first once-weekly topical product for the treatment